Skip to main content
. 2020 Dec 16;17(5):1442–1449. doi: 10.1080/21645515.2020.1833578

Figure 4.

Figure 4.

Percentages of children with seroresponse against hypervirulent MenC strains

95% CI, 95% confidence interval; N, number of children; Group 1_MenACWY, MenACWY-CRM vaccination at 12 months of age; Group 1_MenC, MenC-CRM vaccination at 12 months of age. Seroresponse was defined for children with Visit 3 hSBA titer <1:4 as an hSBA titer ≥1:8 at Visit 4, and for children with Visit 3 hSBA titer ≥1:4 as a ≥ 4-fold rise in hSBA titers at Visit 4.